FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
SHA: 688176
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...